Nitrates have been a major part of the internist's pharmacopoeia for more than 100 years, predominantly for the relief of anginal symptoms. The effects of nitroglycerin on the eye and specifically on intraocular pressure has been investigated with diverse results. However, nitroglycerin may also serve to protect retinal ganglion cells against glutamate mediated toxicity-a form of cell death that may be critical in glaucomatous blindness. Consequently, we therefore sought to evaluate whether nitroglycerin preparations, taken for non-ophthalmic reasons, had an effect on glaucomatous damage.
Introduction
Glaucoma is a disease that is generally characterized by a slow, chronic, progressive optic neuropathy in the presence of an elevated intraocular pressure [1] . Histologically, the optic neuropathy seen in glaucoma is due to the loss of retinal ganglion cells and the degeneration of their axons [1] . The chronic nature of this disease is suggestive of a low level of insult with a cumulative deleterious effect on retinal ganglion cells. Theories regarding the pathogenesis of optic nerve damage in primary open angle glaucoma fall into two broad categories, mechanical and ischemic. Pressure-mediated damage of the optic nerve is hypothesized to be the result of either a direct mechanical effect (trauma hypothesis) or by a compromise of the vasculature (ischemia hypothesis). These insults may damage axons at the lamina cribrosa with subsequent death of the retinal ganglion cells. Current therapy for most forms of glaucoma is directed at lowering the intraocular pressure in an attempt to interrupt or abort the sequence of events that putatively result in death of retinal ganglion cells.
Nitrates have been a major part of the internist's pharmacopoeia for more than 100 years, predominantly for the relief of anginal symptoms [2] . In 1915, Wessely first reported that the administration of amyl nitrite led to an increase in intraocular pressure (IOP) in the cat [3] . Since this initial report, the effects of nitroglycerin in patients with glaucoma have received much attention with inconclusive results [4] [5] [6] [7] [8] . Various investigators have reported that nitrates have deleterious, salubrious or no effect on glaucoma patients. Wizemann and Wizemann reported that a short course of organic nitrates led to a drop in IOP [9] . Hessemer and Schmidt found a minimal drop in IOP with oral nitrates, but did find significant declines in ocular perfusion pressures, raising concerns about possible vascular compromise [10] . Nathanson and colleagues have demonstrated that topical nitroglycerin can lower IOP in glaucoma patients, probably because of the ability of nitroglycerin and related compounds to activate guanylate cyclase and thereby modulate IOP [11, 12] .
However, nitroglycerin may also serve to protect retinal ganglion cells against glutamate mediated toxicity -a form of cell death that we have suggested may be critical in glaucomatous blindness. Nearly four decades ago, Lucas and Newhouse demonstrated that a single subcutaneous injection of glutamate into young mice resulted in selective damage to the retinal ganglion cell layer [13] . Glutamate can cause an optic nerve degeneration that is identical to that seen in glaucoma [14] .
We and others have shown that the concentration of glutamate in glaucomatous vitreous is potentially toxic to retinal ganglion cells [15 -17] . Glutamate toxicity is predominantly mediated through activation of the Nmethyl-D-aspartate (NMDA) subtype of glutamate receptor. If glutamate is indeed part of the pathophysiology of the neuronal loss in glaucoma, then agents that perturb the N-methyl-D-aspartate receptor might affect the course of the disease.
Multiple pharmacological sites on the N-methyl-Daspartate receptor modulate its activity [18] . The redox modulatory site consists of multiple thiol (or sulfhydryl) groups forming one or more disulfide bonds on the receptor [19] . This site is of particular interest since it acts as a 'gain' control for current flux through NMDA receptor-operated channels and can affect neurotoxicity produced by excessive NMDA receptor activation [20, 21] . Reducing agents enhance the activity of the NMDA receptor; oxidizing agents can form disulfide bonds from vicinal or paired free thiol groups and decrease NMDA receptor function and block neurotoxicity [22] .
Nitroglycerin (NTG) and other drugs that generate nitric oxide (NO) can down-regulate NMDA receptor function by oxidizing this redox modulatory site [23, 24] . These common nitrovasodilator drugs may, under certain circumstances, ameliorate NMDA receptor-mediated neurotoxicity [23, 22] .
Inasmuch that we have suggested that glutamate may play a role in the visual loss seen in glaucoma [15] , nitroglycerin is an excellent candidate drug for limiting such glutamate mediated damage in the retina. Nitroglycerin can modulate the NMDA receptor via NO-related species [23, 22] . Given these data and hypotheses in toto, we therefore sought to evaluate whether nitroglycerin preparations, taken for non-ophthalmic reasons, had an effect on the rate of glaucomatous damage.
Materials and methods
A total of 60 patients of the Glaucoma Consultation Service at the Massachusetts Eye and Ear Infirmary were retrospectively identified who met the following inclusion criteria: (1) a diagnosis of hypertensive open angle glaucoma with an elevated IOP (\ 21 mm Hg on at least one visit), no evidence of pseudoexfoliative changes, transillumination defects, or Krukenberg spindle, a gonioscopic report of open angles and evidence of optic neuropathy consistent with glaucoma; (2) a history of taking one of several long-acting nitroglycerin preparations (isordil, nitropaste or nitropatch) for an 8 year period and (3) the availability of at least two sets of both optic nerve stereo photographs and visual field examinations over the same 8 year period. The initial entry date into the study was defined by presentation to the Glaucoma Consultation Service, when patients underwent both optic nerve photographs and visual field examinations. It is not possible to establish how many patients had previously been accurately diagnosed with glaucoma before presentation. Patients were excluded if they were not continuously on nitrates throughout the 8 year period (medication histories were evaluated at each visit). Patients with low tension glaucoma were excluded, as were those who were only taking sublingual nitroglycerin.
A total of 60 patients were identified who had not taken nitrates during a similar period. These patients were matched for age, the presence or absence of visual field loss on presentation and diagnosis with open angle glaucoma. Intraocular pressures and medication histories were recorded for all patients.
Optic nerve changes indicative of glaucoma included the presence of optic nerve asymmetry (i.e. a difference of more than 0.2 in cup-to-disc ratios between the two eyes), evidence of progressive enlargement of the optic cup, notching of the nerve rim, vertical elongation of the cup, splinter hemorrhage, or nasal displacement of the vessels [25] . Visual fields were performed on either the Goldmann or Humphrey perimeters. Minimal reliability criteria for the Humphrey visual fields were B 20% fixation losses, or B33% false negatives or positives. Any visual field test that did not meet these criteria was not included and the first subsequent acceptable visual field utilized. Goldmann visual field defects were to the III4e stimulus or greater and were larger than 5°. Humphrey visual field defects encompassed three adjacent test stimuli and were 5 dB or greater. One eye (selected at random) was evaluated for each patient. Visual fields and optic nerve photographs were analyzed in a masked fashion by two examiners. The investigators were masked as to whether the patients were taking systemic nitrates or not. Deterioration was defined as deepening or enlarging of a scotoma, or the identification of a new area of visual field loss (as defined above). Optic nerve deterioration was defined as any evidence of glaucomatous change in the contour, vasculature, or depth of the cup. Each set of photographs and visual fields were analyzed twice. If any three evaluations were considered as indicating deterioration, the patient was said to have progressed. Each patient could only be scored as having progressed once for either visual field or optic nerve.
Statistical analysis
Demographic characteristics were compared between the two groups using a two-sample Student's t-test for continuous data or Fisher's exact test for proportional data. The kappa statistic was used to measure interobserver agreement [26] . Multiple logistic regression was performed to analyze response data for each binary end point: optic nerve deterioration and visual field deterioration. The likelihood ratio chi-square test was used to assess the significance of nitrates after controlling for intraocular pressure in the model [27] . Kaplan -Meier survival curves were compared between the two groups using the log-rank test to assess the time-related effects of treatment [28] . Cox's proportional hazards model was used to analyze time to either optic nerve or visual field deterioration by simultaneously adjusting for IOP as a covariate and testing for significance of treatment in the multivariate model [29] . Log hazards ratios and standard errors were estimated and were used to calculate confidence intervals on the hazards ratio with lower confidence limits] 1.25 to indicate whether nitrates were significantly superior to control in reducing the risk of optic nerve or visual field deterioration. Additional analyses were performed to assess the effects of optic nerve deterioration as a potential risk factor for visual field deterioration and to evaluate whether IOP was a risk factor for each end point. Two-tailed values of PB 0.05 were considered significant throughout. Data analysis was conducted with the SPSS statistical package, version 6.1 (SPSS, Chicago, IL).
Results
Intraobserver and interobserver reliabilities were both excellent (K\ 0.90). Control and patients receiving nitrates were well-matched for age, sex and race. Patient demographics are summarized in Table 1 . Patients receiving nitrates were slightly but not significantly older than control patients (P = 0.08). There were no differences in the distribution of males and females between the two groups (P = 0.58) and no difference in the distribution of race (P = 0.24). Both groups had similar proportions of patients receiving intraocular surgery (P = 0.64), although more control patients received laser surgery (35% versus 13%, PB 0.01). The mean (9 S.D.) intraocular pressures (averaged IOP measurements for all visits during the 8-year period) for the control and nitrate groups were 18.09 2.6 and 17.39 2.8 mm Hg, respectively (P= 0.15).
Logistic regression analysis established that optic nerve deterioration and visual field deterioration was significantly lower in the nitrate group (PB 0.0001 and P= 0.02, respectively). Deterioration of the optic nerve occurred in 24 control patients (40%) and 15 nitrate patients (25%). The mean time (9 S.E.) to optic nerve deterioration of 759 4 and 849 3 months for control and treatment groups, respectively (P B 0.05, log-rank test). The Kaplan-Meier plot in Fig. 1 shows a slower rate of optic nerve deterioration for the nitrate group over time.
Deterioration of the visual field occurred in 17 control patients (28.3%) and 9 nitrate patients (15%). Mean time (9 S.E.) to visual field deterioration was 8393 and 939 2 months for control and treatment groups, respectively (P= 0.05, log-rank test). The KaplanMeier survival curves for visual field deterioration are presented in Fig. 2 . The log-rank test suggests that treatment may retard the rate of visual field deterioration, however this effect is brought out more strongly in the multivariate analysis. Specifically, by simultaneously controlling for IOP in the Cox proportional hazards model, the monthly risk was about 20 times lower for optic nerve deterioration and four times lower for visual field deterioration among nitrate patients. The estimated optic nerve deterioration hazards ratio for control versus treatment was 19.88 (95% confidence interval, 7.60-52.08, P B 0.0001). Similarly, the visual field deterioration hazards ratio was estimated at 4.21 (95% CI, 1.75-10.09, P = 0.001).
A total of 19 of the 39 patients (48.7%) who had optic nerve deterioration compared to only seven of the 81 patients without optic nerve deterioration (8.6%) had visual field deterioration (P B 0.0001). Logistic regression estimated a 10-fold increase in the odds of visual field deterioration for patients with compared to those without optic nerve deterioration (odds ratio= 10.04, 95% CI= 3.97 -24.85). Moreover, visual field deterioration occurred significantly faster among patients with compared to those without optic nerve deterioration (mean time (9 SE), 72 9 4 month versus 949 1 month, PB0.0001, log-rank test).
Discussion
These results support the surprising conclusion that the concurrent administration of nitrates for non-glaucomatous reasons is beneficial in terms of retarding both visual field loss and glaucomatous optic neuropathy. There are several flaws inherent in our study, however, that cannot be overlooked. First and foremost, we were not able to control adequately for the 'cardiac' health of our nitrate population. Those patients in the nitrate group were presumably in poorer cardiac health, at least with respect to anginal symptoms. This may induce a confounding variable as well with respect to compliance -patients who are taking nitrate preparations to avoid anginal symptoms may be more compliant with all medications. These two issues can only be addressed by the prospective administration of nitrates to a glaucomatous population without cardiac compromise. That is beyond the scope of this study.
The predicted findings: (1) that optic nerve and visual field deterioration were correlated and (2) that intraocular pressure was predictive of both, supports the methodology employed in this study.
Putting these caveats aside, however, there are several explanations to account for the potential beneficial effects of nitrates on the glaucomatous eye. Systemic nitrates may have an effect on the intraocular pressure. Although our analysis does not support this hypothesis, our sample size may not suffice to uncover it. Although we found no significant difference in overall intraocular pressure, nitrates may induce a lower pressure in the diurnal cycle that is not detectable by routine clinical tonometry. Alternatively, the chronic use of nitrates may have a beneficial effect on the optic nerve vasculature. In collaboration with Grunwald and DuPont we have found that patients receiving long term nitrate therapy have larger retinal vessels than controls [30] .
Chronic glutamate mediated ganglion cell excitotoxic damage may play a role in glaucomatous optic neuropathy [15] [16] [17] . Animals maintained on chronic nitroglycerin preparations are resistant to such an excitotoxic challenge [31] . Consequently, nitrate preparations may be directly neuroprotective, rendering retinal ganglion cells more resistant to the toxic effects of the glaucomatous process. Chronic nitrate therapythrough its ability to downregulate sensitivity to glutamate-may protect retinal ganglion cells against glaucoma associated excitotoxicity.
Regardless of mechanism of action, our data suggest that concomitant use of systemic nitrates in glaucoma patients may offer a protective effect against glaucomatous optic neuropathy. Given the inherent flaws in our retrospective study, a prospective study may provide further information. It may be more appropriate for additional retrospective data to be collected first. However, it is potentially intriguing that agents known to perturb the N-methyl-D-aspartate subtype of glutamate receptor also retard glaucomatous damage. Fig. 2 . Kaplan -Meier survival curves for visual field deterioration comparing nitrate and control groups. Univariate analysis suggested that visual field deterioration was faster for control patients (log-rank test, P= 0.05). The effect of nitrates on retarding the rate of visual field deterioration was more evident in the multivariate Cox regression model when simultaneously controlling for intraocular pressure (PB 0.0001).
